Biogen has state-of-the-art, global manufacturing facilities in the US and Denmark, representing nearly 200,000 litres of bioreactor capacity, among the largest of biotechnology companies worldwide. For example, at our manufacturing facility in Hillerød, Denmark, we have a capacity of 90,000 litres to produce originator molecules and biosimilars of advanced biologics.
Leveraging our manufacturing excellence, we have gained a deep understanding of what it takes to consistently manufacture advanced biologics and to tightly control our processes to minimise product quality variations that can result in supply disruptions. And our extensive manufacturing capacity allows us to independently manage and build redundancies within our supply chain, thereby providing confidence that a consistent and reliable supply of medicines will be available for patients, healthcare providers, and payers when and where they need them. Manufacturing matters when it comes to biosimilars of advanced biologics.